The N-methyl-D -aspartate antagonist memantine has no neuroprotective effect during hypothermic circulatory arrest: A study in the chronic porcine model  by Rimpiläinen, Jussi et al.
However, the efficacy of hypothermia is limited and the
safe duration of HCA is 40 to 50 minutes at brain tem-
peratures of 10°C to 15°C.3 The importance of the fail-
ure of neurotransmitter transport as a common pathway
in the pathogenesis of ischemic cerebral injury has been
well demonstrated in the past few years.4-6 Under condi-
tions of depleted cellular energy, including hypoxia and
ischemia, glutamate is accumulated in the intercellular
space, acting as a neurotoxic substance. It opens calcium
channels, leading to an influx of calcium, which initiates
the catastrophic cascade that eventually leads to neu-
ronal autodigestion and cell death.6,7 Excitatory amino
Hypothermic circulatory arrest (HCA) is a frequentlyused method during operations on the aortic arch.1,2
Background: Glutamate excitotoxicity has an important role in the develop-
ment of brain injury after prolonged hypothermic circulatory arrest. The goal
of the present study was to determine the potential efficacy of memantine, an
N-methyl-D-aspartate receptor antagonist, to mitigate cerebral injury after
hypothermic circulatory arrest.
Methods: Twenty pigs (23-33 kg) were randomly assigned to receive meman-
tine (5 mg/kg) or placebo in a blinded fashion before a 75-minute period of
hypothermic circulatory arrest at 20°C. Hemodynamic, electroencephalo-
graphic, and metabolic monitoring were carried out. The intracerebral concen-
trations of glucose, lactate, glutamate, and glycerol were measured by means
of enzymatic methods on a microdialysis analyzer. Daily behavioral assess-
ment was performed until the animals died or were put to death on day 7.
Histologic analysis of the brain was carried out in all animals.
Results: In the memantine group, 5 of 10 animals survived 7 days com-
pared with 9 of 10 in the placebo group. The median behavioral score at
day 7 was 3.5 in the memantine group and 7.5 in the placebo group (P >
.2). Among the surviving animals, medians were 9.0 and 8.0 on day 7 (P
> .2), respectively. The medians of recovered electroencephalographic
bursts were equal in both groups. The median of total histopathologic
score was 16 in the memantine group and 14 in the placebo group (P > .2).
There was a negative correlation between glutamate levels and electroen-
cephalographic burst recovery (τ = –0.377, P = .043). A positive correla-
tion was found between the highest individual glutamate value and
histopathologic score (τ = 0.336, P = .045).
Conclusions: The present study demonstrates that memantine has no neuro-
protective effect after hypothermic circulatory arrest in the pig. In addition,
we have shown the accuracy of cerebral glutamate measurements to predict
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acid antagonists are used to prevent the development of
ischemic brain injury, but their clinical use is frequently
limited because of neurotoxic side effects.7
Memantine is an uncompetitive N-methyl-D-aspartate
(NMDA) receptor antagonist. It is widely used as a
very well tolerated drug in the treatment of chronic
neurodegenerative diseases such as Parkinson disease,
Alzheimer disease, and acquired immunodeficiency
syndrome. It is also used as a symptomatic treatment
for epilepsy and depression.8-10 Memantine ameliorates
NMDA receptor–mediated neurotoxicity in vitro and in
vivo in normothermia.11,12 Memantine has also proved
to be a promising drug in the treatment of retinal
ischemia.13,14 The results of experimental studies using
memantine for prevention of spinal cord injury induced
by ischemia have been controversial.15-17
We have been studying the means to ameliorate brain
injury after HCA in a chronic porcine model.18,19 The
aim of this study was to test the neuroprotective effica-
cy of memantine during HCA with this model.
Materials and methods
Twenty juvenile (8- to 10-week-old) female pigs of a native
stock, weighing 23 to 33 kg, were randomly assigned to
receive either memantine (5 mg/kg) or placebo (saline solu-
tion) before a 75-minute period of HCA at 20°C.
Preoperative management. All animals received humane
care in accordance with the “Principles of Laboratory Animal
Care” formulated by the National Society for Medical
Research and the “Guide for the Care and Use of Laboratory
Animals” prepared by the Institute of Laboratory Animal
Resources and published by the National Institutes of Health
(NIH publication No. 85-23 revised 1985). The study was
approved by the Research Animal Care and Use Committee
of the University of Oulu.
Pharmacokinetic pilot study of memantine. Therapeutic
range of plasma levels in patients treated with memantine
(10-30 mg per day) is 0.2 to 1.0 µmol/L and free brain inter-
stitial concentration is 20% to 30% lower than in plasma.10
Plasma concentrations of 1 µmol/L are achieved in laborato-
ry animals after acute injection of 2.5 to 5.0 mg/kg.20 To
determine the appropriate dose of memantine in the pig, we
performed a pharmacokinetic pilot study in 4 pigs weighing
25 kg. Memantine doses of 3, 5, 7, and 10 mg/kg were given
and blood samples were obtained 30 minutes, 1 hour, 2 hours,
and 5 hours after the start of drug administration. A plasma
level of 1.49 µmol/L was recorded 30 minutes after a dose of
3 mg/kg. Animals in this model are known to be exposed for
rather severe global cerebral ischemia18,19 and, on the other
hand, plasma is diluted by cardiopulmonary bypass (CPB).
Therefore, a dose of 5 mg/kg providing the highest blood
level of 2.81 µmol/L 30 minutes after drug administration
was selected for the study.
Drug administration. Memantine was diluted in sodium
chloride 0.9% to obtain a solution containing memantine at
10 mg/mL, and this was packed in 15 mL ampules in the
Pharmaceutical Laboratory of Oulu University Hospital.
Saline placebo ampules were prepared similarly. A dose of 5
mg/kg was measured and diluted to 50 mL in saline solution.
This volume was given intravenously over a period of 20
minutes, starting 75 minutes before HCA. Randomization
was carried out by the chemist in the pharmaceutical labora-
tory, and the codes were broken after the entire series of
experiments were accomplished. Therefore, all observers in
every data recording point were unaware of whether the ani-
mal was a memantine subject or a control subject.
Pharmacokinetic analyses, generously performed by Merz &
Co, demonstrated that memantine concentrations in the study
group were sustained at a therapeutically relevant level
throughout the critical period of the experiment. The median
(interquartile range) plasma concentrations of memantine
showed a slow tapering after the period of rewarming as fol-
lows: 1.23 µmol/L (0.98-1.46 µmol/L) at the end of cooling
at 20°C, 1.47 µmol/L (1.35-1.65 µmol/L) during rewarming
at 30°C, 1.12 µmol/L (0.96-1.19 µmol/L) 2 hours after the
start of rewarming, 0.66 µmol/L (0.56-0.79 µmol/L) 4 hours
after the start of rewarming, and 0.46 µmol/L (0.43-0.62
µmol/L) 7 hours after the start of rewarming. 
Anesthesia and hemodynamic monitoring. Anesthesia
was induced with medetomidine hydrochloride (0.4 mg/kg
intramuscularly), and muscular paralysis was maintained
with pancuronium bromide (0.1 mg/kg intravenously). After
endotracheal intubation, the animals were maintained on pos-
itive-pressure ventilation with 35% oxygen; anesthesia was
maintained with isoflurane (1.1%-1.2%). The arterial catheter
was positioned in the left femoral artery. A thermodilution
catheter (CritiCath, 7F; Ohmeda GmbH & Co, Erlangen,
Germany) was placed through the femoral vein to allow
blood sampling, pressure monitoring in the pulmonary artery,
and recording of cardiac output. The intracranial temperature
probe was placed through a drill hole in the epidural space.
The drill hole was positioned 1 cm to the left side from a
sagittal joint above a parietal line. Other temperature probes
were placed in the esophagus and rectum, and a 10F catheter
was placed in the urinary bladder to monitor urine output. 
Electroencephalographic (EEG) monitoring. Cortical
electrical activity was registered from 4 stainless steel screw
electrodes (5 mm in diameter) implanted in the skull over the
parietal and frontal areas of the cortex with a digital EEG
recorder (Nervus Company, Reykjavik, Iceland) and an
amplifier (Magnus EEG 32/8; Nervus Company). Sampling
frequency was 1024 Hz, and bandwidth was 0.03 to 256 Hz.
All EEG recordings are referenced to a frontal screw elec-
trode, which, together with a ground screw electrode, is
implanted over the frontal sinuses. Isoflurane level was
adjusted so that the EEG showed a steady burst suppression
pattern. After this, isoflurane end-tidal was kept at this steady
level until the end of monitoring. The EEG was recorded for
10 minutes to get a baseline recording of steady burst sup-
pression activity before the cooling period. After HCA, EEG
recording was restarted and continued until the first postop-
erative day. The durations of EEG were measured from 5-
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minute EEG samples at fixed time points, first with half-hour
intervals, later with 1-hour intervals. From each 5-minute
sample artifact periods were excluded, and from the rest the
sum of bursts was counted as percentage of the sum of arti-
fact-free bursts and suppressions. This percentage was used
as a measure of EEG activity in the analysis. 
CPB. Through a right thoracotomy in the fourth intercostal
space, the right thoracic artery was ligated, and the heart and
great vessels were exposed. A membrane oxygenator
(Midiflow D 705; Dideco, Mirandola, Italy) was primed with
1 L of Ringer acetate and heparin (5000 IU). After hepariniza-
tion (300 IU/kg), the ascending aorta was cannulated with a
16F arterial cannula and the right atrial appendage with a sin-
gle 24F atrial cannula. Nonpulsatile CPB was initiated at a
flow rate of 100 mL · kg–1 · min–1 and the flow was adjusted
to maintain a perfusion pressure of 50 mm Hg. A 12F intra-
cardiac sump cannula was positioned in the left ventricle for
decompression of the left side of the heart during CPB. A heat
exchanger was used for core cooling. The pH was maintained,
using alpha-stat principles, at 7.40 ± 0.05 with an arterial PCO2
of 4.0 to 5.0 kPa, uncorrected for temperature. All measure-
ments were performed at 37°C.
A cooling period of 60 minutes was carried out to attain
a rectal temperature of 20°C. The ascending aorta was
crossclamped just proximal to the aortic cannula. Cardiac
arrest was induced by injecting potassium chloride (1
mEq/kg) via the aortic cannula, and topical cardiac cooling
was then begun and maintained throughout the aortic cross-
clamp period.
Experimental protocol. After cooling to 20°C rectal tem-
perature and crossclamping of the aorta, the animals under-
went a 75-minute interval of HCA with the head packed in
ice. After this 75-minute period, CPB rewarming was initiat-
ed. The left ventricular vent cannula was removed. Weaning
from CPB occurred approximately 60 minutes after the start
of rewarming with administration of furosemide (40 mg),
mannitol (15 g), methylprednisolone (80 mg), and lidocaine
(40-150 mg). Cardiac support was provided by dopamine (1-
5 mg/h). The animals were kept under isoflurane anesthesia
until the following morning, extubated, and moved into a
recovery room. 
During the experiments, hemodynamic and metabolic mea-
surements were recorded at 5 time points as follows: at base-
line; at the end of cooling (at 20°C, immediately before insti-
tution of the intervention); during rewarming (at 30°C); 2
hours after the start of rewarming; and 4 hours after the start
of rewarming.
Postoperative evaluation. Postoperatively, all the animals
were evaluated daily by an experienced observer who was
blinded to the study group. The observer used a species-
specific quantitative behavioral score as reported earlier.21
The assessment quantified mental status (0 = comatose, 1 =
stuporous, 2 = depressed, 3 = normal), appetite (0 = refuses
liquids, 1 = refuses solids, 2 = decreased, 3 = normal), and
motor function (0 = unable to stand, 1 = unable to walk, 2 =
unsteady gait, 3 = normal). Numerical summing of these
functions provides a final score: the maximum (score of 9)
reflects apparently normal neurologic function, whereas
lower values indicate substantial brain damage. A score of 8
means that the animals were able to stand unassisted and
were likely to recover fully. Each surviving animal was elec-
tively killed on day 7 after the operation. The entire brain was
immediately harvested and weighed for subsequent histolog-
ic analysis.
Histopathologic analysis. During autopsy the brain was
excised immediately and the hemispheres were separated.
One half was immersed in 10% neutral formalin solution and
allowed to fix for 1 to 2 weeks en bloc. Thereafter, 3-mm
thick coronal samples were sliced from the frontal lobe, thal-
amus (including the adjacent cortex), and hippocampus
(including the adjacent brain stem and temporal cortex), and
sagittal samples were obtained from the posterior brain stem
(medulla oblongata and pons) and cerebellum. The pieces
were fixed in fresh formalin solution for another week. After
the fixation, the samples were processed as follows: rinsing
in water for 20 minutes, immersion in 70% ethanol for 2
hours, in 94% ethanol for 4 hours, and in absolute ethanol for
9 hours. Thereafter, the pieces were kept 1 hour in absolute
ethanol-xylene mixture, 4 hours in xylene, and were embed-
ded in warm paraffin for 6 hours. The samples were sectioned
at 6 µm and stained with hematoxylin and eosin. The sections
of the brain samples of each animal were screened by a sin-
gle experienced senior pathologist (J.H.), unaware of the
experimental design and of the identity and fate of individual
animals. Each section was carefully investigated for the pres-
ence or absence of any hypoxic or other damage.
Visual estimation of the injuries in the sampled regions was
made as follows: 0 = no morphologic damage; 1 = edema or
eosinophilic dark neurons or dark/shrunk cerebellar Purkinje
cells; 2 = at least 2 small hemorrhages, and 3 = clearly infarc-
tive foci. Total score is the sum of scores in each specific
brain area (cortex, thalamus, hippocampus, posterior brain-
stem, and brainstem). To allow semiquantitative comparisons
between the animals, we calculated a total histologic score by
adding all the regional scores. A score more than 4 means that
the animal had a distinct brain injury.
Microdialysis. The microdialysis catheter (CMA 70;
CMA/Microdialysis, Stockholm, Sweden) was placed into
the brain cortex. A drill hole was positioned 1 cm to the right
side from a sagittal joint above a parietal line. The shaft was
introduced free hand through a bolt to a depth of 15 mm
below the dura. The microdialysis catheter was connected to
a 2.5-mL syringe placed in a microinfusion pump (CMA107;
CMA Microdialysis) and perfused with Ringer solution
(Perfusion Fluid; CMA Microdialysis). Samples were col-
lected every 30 minutes. The concentrations of glucose, lac-
tate, glutamate, and glycerol were measured immediately
after collection by means of ordinary enzymatic methods on
a microdialysis analyzer (CMA 600; CMA Microdialysis).
Other measurements. Systemic arterial and venous blood
samples were obtained to determine pH, PO2, PCO2, oxygen
saturation, oxygen content, hematocrit value, hemoglobin
concentration, and glucose level (Ciba-Corning 288 Blood
Gas System; Ciba-Corning Diagnostic Corp, Medfield,
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Mass). Lactate was analyzed by means of a YSI 1500 analyz-
er (Yellow Springs Instrument Co, Yellow Springs, Ohio).
Statistical analysis. Summary statistics for continuous or
ordinal variables are expressed as the median with interquar-
tile range (25th and 75th percentiles) or means with standard
deviation (SD). In the figures, values are shown as medians
with interquartile ranges.
The analysis was performed by analysis of variance for
repeated measurements. Comparison between relevant time
points and baseline (reference category) was performed by
paired sample t test or Wilcoxon matched pairs signed rank
test. Differences between groups were determined by t test or
by the Mann-Whitney U test. The 2-tailed Fisher exact test
was used to determine the significance of mortality rates
between groups. The area under the curve (AUC) was calcu-
lated for microdialysis measurements, and Kendall’s rank
correlation was used to estimate correlation coefficients.
Analyses were performed with a standard commercially




Comparability of experimental groups. The mean
(±SD) weight of the animals was 28 ± 3 kg in the
memantine group and 29 ± 2 kg in the placebo group.
The mean (±SD) CPB cooling time was 66 ± 6 minutes
in the memantine group and 66 ± 5 minutes in the con-
trol group. Rewarming times were 69 ± 7 minutes and
76 ± 7 minutes, respectively. Temperatures during the
experiments did not differ between the groups (Fig 1).
Hemodynamic data. All animals were in stable con-
dition before, during, and after CPB. As seen in Table
I, mean arterial pressure decreased in both groups com-
pared with baseline at the end of cooling, during
rewarming at 30°C, 2 hours after the start of rewarm-
ing, and 4 hours after start of rewarming (P < .001).
Cardiac output decreased when compared with base-
line in the memantine group 4 hours after start of
rewarming (P = .033) (Table I). Vascular resistance
decreased in the memantine group compared with the
baseline group at the end of cooling and during
rewarming at 30°C (P = .001 and P < .001). Vascular
resistance decreased also in the placebo group at the
same time points compared with baseline (P = .003 and
P = .025) (Table I). The minor differences in hemody-
namic data between the groups could be due to chance
(P > .2) (Table I).
Blood gas and hematocrit measurements are shown
in Table I. Both in memantine and placebo animals a
decrease in pH was detected at the end of cooling 
(P < .001) and 2 hours after the start of rewarming
compared with baseline (P = .034 and P = .006), but
the difference between the groups could be due to
chance (P > .2). Arterial PCO2 was higher in both
groups at the end of cooling than baseline (P = .002
and P < .001). In the placebo group, arterial PCO2 was
lower during rewarming at 30°C (P = .024) and high-
er 2 hours and 4 hours after the start of rewarming 
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Fig 1. Epidural temperatures of 20 pigs receiving either memantine (5 mg/kg) or placebo before a 75-minute peri-
od of HCA. Values are shown as medians with interquartile ranges.
(P = .034 and P = .001), but no significant differences
between the groups were detected; the difference
between the groups could be due to chance (P > .2).
Hematocrit was lower at the end of cooling and dur-
ing rewarming at 30°C in both groups (P < .001) and
in the placebo group 2 hours after the start of rewarm-
ing (P = .011), but the difference between the groups
could be due to chance (P > .2).
Metabolic data. The venous lactate level after base-
line increased at all recording points among control
animals (P < .001). The same increase was also seen in
memantine animals (P = .029, P < .001, P = .001, and
P = .064), respectively. Oxygen extraction and con-
sumption decreased in memantine animals (P = .058
and P = .038) and in controls (P < .001 and P = .010)
at the end of cooling. The differences in the oxygen
extraction and consumption between the groups could
be due to chance (P > .2) (Table II).
EEG. The pattern of EEG outcome was similar in
both groups, and minor differences in median rate of
EEG burst recovery could be due to chance (P > .2)
(Fig 2).
The Journal of Thoracic and
Cardiovascular Surgery
Volume 121, Number 5
Rimpiläinen et al 961
Fig 2. EEG burst recovery of 20 pigs receiving either memantine (5 mg/kg) or placebo before a 75-minute period
of HCA.
Fig 3. Daily scores indicating behavioral recovery among 20 pigs receiving either memantine (5 mg/kg) or place-
bo before a 75-minute period of HCA. A score of 8 or 9 indicates essentially complete recovery, lower scores indi-
cate substantial impairment, and 0 indicates coma or death. 
Morbidity and mortality. All animals were in stable
condition during the surgical procedures and survived
at least to the first postoperative day. Fourteen of the 20
animals survived 7 days after the operation and were
electively killed. In the memantine group, 5 of 10 ani-
mals survived 7 days compared with 9 of 10 in the
placebo group (P = .14).
Behavioral outcome. The results of behavioral scoring
for both groups are shown in Fig 3. Scores of 8 and 9
indicate an essentially complete neurologic recovery.
Animals that died early were given a score of 0 beginning
at the time of death. The median behavioral score on day
7 was 3.5 in the memantine group and 7.5 in the placebo
group (P > .2). Among the surviving animals, medians
were 9.0 and 8.0 on day 7 (P > .2), respectively.
Histopathologic results. Some representative
histopathologic slides from memantine and placebo ani-
mals depicting severe and minor ischemic injury are
given in Fig 4. In terms of histopathologic findings, there
were no statistically significant differences between the
groups (Table III). The total histopathologic score was
calculated by adding the scores of histopathologic find-
ings in the investigated regions of the brain for each of
the animals. The median of the total histopathologic
score was 16 in the memantine group and 14 in the
placebo group (P > .2) (Fig 5).
Microdialysis. The intracerebral glucose concentra-
tion decreased during cooling and HCA and returned to
baseline with no statistically significant differences
between the groups (Fig 6). Lactate concentration
increased 30 minutes after HCA in both groups, the
highest peak being found 1 hour after the start of
rewarming. After this recording point, lactate
decreased to the level slightly higher than baseline in
both groups (Fig 6). AUC was calculated from the start
of HCA to 7 hours after the start of rewarming, but the
difference between the groups could be due to chance
(P > .2). As seen in Fig 6, median glutamate levels
exhibited peak values 30 minutes after the start of
rewarming and decreased after this recording point to
approximately zero. The median glutamate concentra-
tion was higher in the memantine group (49 µmol/L)
than in the placebo group (23 µmol/L) 30 minutes after
the start of rewarming, but the difference could be due
to chance (P > .2). The difference of glutamate’s AUC
between the groups could be due to chance (P > .2).
Glycerol also showed a peak after HCA, but the high-
est point occurred a bit later than the glutamate peak
(Fig 6). The difference of AUC for glycerol between
the groups could also be due to chance (P > .2). 
Because there were no statistically significant differ-
ences in AUC values between the groups in microdial-
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Table I.  Hemodynamic data, blood gases, and hematocrit values in 20 pigs undergoing either memantine (5 mg/kg) 
or placebo administration before a 75-minute period of HCA
Group N Baseline (37°C) End of CPB cooling (20°C)
MAP (mm Hg)
Memantine 10 95 (88-105) 53 (50-58)‡
Placebo 10 96 (91-103) 56 (49-59)‡
Cardiac output/CPB flow (L/min)
Memantine 10 2.3 (2.2-2.8) 2.5 (2.3-2.8)
Placebo 10 2.5 (2.5-3.0) 2.6 (2.4-3.0)
Vascular resistance (dyne · s–1 · cm–5)
Memantine 10 3055 (2273-3331) 1686 (1336-1809)‡
Placebo 10 2890 (2359-3158) 1761 (1538-1821)‡
Arterial pH
Memantine 10 7.5 (7.4-7.5) 7.2 (7.2-7.3)‡
Placebo 10 7.5 (7.4-7.5) 7.2 (7.2-7.3)‡
Arterial PCO2 (mm Hg)
Memantine 10 6.3 (5.9-6.5) 8.4 (8.1-8.4)*
Placebo 10 6.2 (5.9-6.2) 8.5 (8.3-8.7)‡
Hematocrit (mg/dL)
Memantine 10 31 (29-33) 18 (16-19)‡
Placebo 10 30 (29-31) 20 (17-21)‡
HCA, Hypothermic circulatory arrest; MAP, mean arterial pressure; CPB, cardiopulmonary bypass; Arterial PCO2, arterial carbon dioxide tension. Values are shown
as medians with interquartile range.
*P < .05 compared with baseline.
†P < .01 compared with baseline.
‡P < .001 compared with baseline.
ysis data, the correlation coefficients were calculated
using all animals. A positive correlation of AUC was
found between glutamate and glycerol (τ = 0.474,
P = .004), but there was no correlation between gluta-
mate and lactate (P > .2). A 1-hour lag was found in
correlation between glutamate peak (30 minutes after
the start of rewarming) and glycerol (from 1.5 hours
after the start of rewarming onward), giving highest
correlation with a lag of 1.5 and 2 hours (τ = 0.537, P
= .001). There was an inverse correlation between the
highest individual glutamate levels and EEG burst
recovery 3 hours after the start of rewarming, the high-
est correlation being (τ = –0.377, P = .043) (Fig 7). In
addition, there was a positive correlation between the
highest individual glutamate value and histopathologic
score (τ = 0.336, P = .045) (Fig 8).
Discussion
In the present study we have evaluated the efficacy of
memantine to protect the brain after experimental
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After start of rewarming
30°C 2 h 4 h
67 (58-70)‡ 69 (68-73)† 74 (70-82)†
67 (58-69)‡ 69 (67-71)‡ 67 (67-82)‡
2.6 (2.2-2.8) 2.6 (1.8-2.8) 2.0 (1.9-2.3)*
2.6 (2.2-2.7) 2.2 (2.0-2.3) 2.2 (2.0-2.8)
1901 (1814-2034)‡ 1968 (1915-2514) 2772 (2326-3069) 
1943 (1742-2360)* 2326 (2047-2584) 2570 (2093-3122)
7.4 (7.4-7.5) 7.4 (7.3-7.4)* 7.4 (7.4-7.4)
7.4 (7.3-7.5) 7.4 (7.3-7.4)† 7.4 (7.4-7.4)
5.5 (5.3-5.8) 6.5 (5.9-6.9) 6.4 (6.3-6.8)
5.5 (5.2-5.8)* 6.7 (6.5-6.7)* 6.7 (6.5-6.8)†
21 (17-23)‡ 29 (26-31) 28 (27-31)
22 (20-23)‡ 27 (26-28)* 29 (27-30)
Table II. Venous lactate levels, oxygen extraction, and oxygen consumption during the experiment in 20 pigs
undergoing either memantine (5 mg/kg) or placebo administration before a 75-minute period of HCA 
Baseline End of CPB cooling
Group N (37°C)q (20°C) 30°C 2 h 4 h
Venous lactate (mmol/L)
Memantine 10 1.0 (0.9-1.3) 1.8 (1.5-2.2)* 5.2 (4.7-5.7)‡ 4.3 (4.0-6.0)‡ 1.7 (1.4-2.5)*
Placebo 10 1.0 (0.9-1.2) 1.6 (1.3-2.3)‡ 4.7 (4.5-6.5)‡ 4.3 (3.9-5.2)‡ 2.0 (1.9-2.2)‡
Oxygen extraction (mmol/L)
Memantine 10 3.8 (2.5-4.2) 1.8 (1.0-2.2)* 3.0 (2.9-3.4) 4.1 (4.0-4.4) 4.5 (4.0-5.5)
Placebo 10 3.7 (3.3-4.1) 1.9 (1.7-2.2)‡ 3.1 (2.7-3.4) 4.6 (4.1-5.1) 4.6 (3.9-5.5)
Oxygen consumption (mL/min)
Memantine 10 89.6 (73.9-94.1) 39.1 (25.2-57.4 )* 80.1 (77.0-89.5) 102.2 (93.4-117.6) 99.4 (82.0-102.3)
Placebo 10 104 (99.9-112.8) 49.9 (42.8-54.8)* 81.4 (71.8-85.8) 100.1 (87.0-107.6) 109.5 (100.3-112.8)
Abbreviations are as in Table I. Values are shown as medians with interquartile range.
*P < .05 compared with baseline.
‡P < .001 compared with baseline.
After start of rewarming
hypothermic ischemia in terms of histopathologic and
various neurologic end points. The major finding was
that pigs receiving memantine before a 75-minute peri-
od of HCA at 20°C tended to have an even poorer out-
come than control animals given a placebo. The mor-
tality rate tended to be higher in memantine animals
and no differences in terms of neurophysiologic,
behavioral, histopathologic, and microdialysis data
were seen. 
The most frequently used method for brain protec-
tion during operations on the aortic arch is hypother-
mia. It has been demonstrated very recently that even
in deep hypothermia (systemic temperature 10°C-
15°C) a significant degree of cerebral metabolic rate of
oxygen consumption remains, and the length of safe
HCA is limited to 40 to 50 minutes.3 The importance
of the failure of neurotransmitter transport as a com-
mon pathway in the pathogenesis of many neurologic
disorders, including ischemic cerebral injury, has been
well demonstrated in the past few years. Excitatory
amino acids, including glutamate and aspartate, are the
primary messengers used for interneuronal communi-
cation.6 After ischemia, glutamate accumulates in the
intercellular space, where it acts as a potent neurotox-
ic substance. It opens calcium channels, leading to an
influx of calcium, which starts the catastrophic intra-
cellular activation of several enzymes.6 This knowl-
edge has opened up new avenues of research to
enhance current protective methods by the addition of
appropriate pharmacologic agents.6,22 The most stud-
ied antagonists are the glutamate receptor blockers and
Ca2+ and Na+ channel antagonists. Despite promising
results in experimental studies with various specific
interventional agents, most of these have turned out to
be neurotoxic in the clinical setting.22 Only a few
potentially neuroprotective pharmacologic agents are
clinically used. Lamotrigine is one of them, and we
demonstrated recently using the same animal model
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Fig 4. A, A 7-day-old local necrosis (infarction) in the frontal
cortex in a memantine-treated pig. The arrow depicts a zone
of new capillaries at the border of the necrosis. In the lesion
(center of figure) neurons are not seen and glial cells and
macrophages are accumulated in this area. The finding was
classified as a third-degree lesion. B, A similar local necrosis
as above in the frontal cortex of a control pig. The arrow
depicts new capillaries. Gliosis and macrophages are also
seen. C, A staining from hippocampus indicates that injured
neurons have turned red, but surviving neurons have normal
color. Edema is seen around the small vessels. The finding
was classified as a first-degree lesion. D, Hemorrhage in
medulla oblongata, classified as a second-degree lesion in our
scale. A few injured red neurons are seen around the bleed-
ing. (A, B, C, and D, Hematoxylin and eosin stain, original
magnification 60×.) 
Fig 5. Total histopathologic scores among 20 pigs receiving
either memantine (5 mg/kg) or placebo before a 75-minute
period of HCA. The total histopathologic score was calculat-
ed by adding the quantitative assessment of histopathologic
findings in the investigated regions of the brain for each of
the animals.
that this antiepileptic drug substantially improved
brain protection during HCA.18 Memantine is an
uncompetitive NMDA receptor antagonist, and it is
well tolerated clinically.10 Previous studies have
shown that memantine carries neuroprotective effects
in chronic neurodegenerative diseases and in acute
ischemia.10,12,14,23 On the contrary, memantine failed
to improve neurologic outcome after ischemic and
traumatic spinal cord injury.15
The finding of equal hemodynamic and physiologic
data between the groups in the present study indicates
that memantine was well tolerated and the setup of this
demanding model was appropriate. In the present
study, there were no differences in total histopatholog-
ic scores between the study groups, medians being 16
in the memantine group and 14 in the placebo group. In
our previous research endeavor studying leukocyte fil-
tration during 75-minute periods of HCA at 20°C, the
median histopathologic score in control animals was
15.5, which indicates that the degree of brain injury in
control animals is stable. In leukocyte-depleted animals
of the same study the median score was 6.5, indicating
that the leukocyte filter was a powerful tool to mitigate
brain injury after HCA.19
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Fig 6. Intracerebral concentrations of lactate, glycerol, glutamate, and glucose of 20 pigs, either memantine (5
mg/kg) or placebo, before a 75-minute period of HCA. Values are shown as medians.
In the present study the mortality rate tended to be
higher in the memantine group (5/10 vs 1/10; P = .14),
but the explanation for this remains obscure. Glutamate
receptor blockers can upregulate the number of glutamate
receptors.24 This phenomenon may account for the para-
doxically enhanced excitatory amino acid–mediated
injury.25 Perhaps this was the reason that the animals
receiving memantine did worse. As seen in Fig 4, early
deaths were very likely due to brain damage, because
there were no major differences in hemodynamic data
and specific comorbid findings were not found during
autopsies. Among the animals that survived for 7 days,
the behavioral scores were equal. As seen in Fig 2, there
were no differences in EEG burst recovery. The EEG data
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Fig 7. Correlation between glutamate levels and EEG burst recovery 3 hours after the start of rewarming of 20 pigs
undergoing a 75-minute period of HCA.
Fig 8. Correlation between highest individual glutamate value and histopathologic score of 20 pigs undergoing a
75-minute period of HCA.
are in line with the other data and confirm that meman-
tine did not protect the brain in this model. 
Our microdialysis facilities provided us with an
opportunity to look at brain continuous biochemistry
during global hypothermic ischemia. As seen in Fig
6, curves were similar in both groups, demonstrating
that memantine had no effect on the intracerebral
concentrations of glutamate and glycerol after this
dose. There were strong correlations between gluta-
mate levels and glycerol levels, the glycerol peak fol-
lowing a bit later. This is in line with previous find-
ings demonstrating that release of glutamate starts
the biochemical cascade and cell damage will follow
later.6 The finding that glutamate levels were not
increased in the brain is not surprising because
memantine is an NMDA receptor blocker and should
not influence the quantity of glutamate. There was
also a correlation between highest individual gluta-
mate levels and histopathologic scores. In addition,
as depicted in Fig 6, a negative correlation between
glutamate levels and EEG burst recovery was found.
These findings support the knowledge that the accu-
mulation of glutamate in the intercellular space is
neurotoxic.26
The finding of failed neuroprotection of memantine
is surprising, and it can speculated that the dosage used
in the current study was too low. However, side effects
such as ataxia, myorelaxation, and amnesia can be
encountered after higher short-term doses such as 20
mg/kg of memantine.10 This was the first study to test
the efficacy of memantine during HCA, and non-
neuroprotective efficacy of memantine in this context
can be related to hypothermia per se. Because the mor-
tality rate tended to be higher in the memantine group,
we believe that this report is of particular importance
inasmuch as memantine has been suggested to improve
neurologic outcome during operations on the thoracic
aorta.16 On the basis of these data, we conclude that
memantine does not have the potential to mitigate cere-
bral injury in patients undergoing HCA. The present
study also supports the previous findings indicating the
pivotal role of glutamate in the pathogenesis of
ischemic brain injury. In addition, these findings shed
more light on the current concept of perioperative
detection of neuronal injury, demonstrating that moni-
toring of intracerebral glutamate levels is an accurate
method to predict ischemic insult.
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Table III.  Histopathologic scores after the experiment in 20 pigs undergoing either memantine (5 mg/kg) 
or placebo administration before a 75-minute period of HCA
Protocol Pig No. Cortex Thalamus Hippocampus Posterior brain stem Cerebellum Total score
Memantine 1 7 1 2 4 4 18
2 4 4 2 3 3 16
3 4 2 2 4 4 16
4 4 1 2 2 1 10
5 4 2 4 2 2 14
6 7 1 7 4 4 23
7 4 2 2 4 4 16
8 4 2 2 4 4 16
9 7 2 2 3 3 17
10 4 4 4 4 3 19
Placebo 1 4 1 2 3 1 11
2 4 4 4 3 4 19
3 7 4 4 3 4 22
4 7 1 2 3 3 16
5 4 2 2 2 1 10
6 5 1 2 2 2 12
7 4 4 2 4 4 18
8 2 2 2 1 2 9
9 4 1 2 4 3 14
10 4 1 2 3 4 14
Scores: 0 = No morphologic damage; 1 = edema or eosinophilic dark neurons or dark/shrunk cerebellar Purkinje’s cells; 2 = at least mild hemorrhage; 3 = clearly
infarctive foci. Total score is the sum of scores in each specific brain area (cortex, thalamus, hippocampus, posterior brain stem, and brain stem). To allow semi-
quantitative comparisons between the animals, we calculated a total histologic score by adding all the regional scores. 
Veikko Lähteenmäki, and Kauko Korpi, RN, for technical
assistance.
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Commentary
In this study Rimpiläinen and colleagues have tested
the hypothesis that an N-methyl-D-aspartate (NMDA)
receptor blocking agent, memantine, might have a neu-
roprotective effect during deep hypothermic circulato-
ry arrest (HCA). Their results, based on somewhat
small experimental groups, suggest that this agent does
not have the hoped for effect. My comments are
focused on neurohistologic assessment and grading,
which is a major instrument in this study and similar to
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procedures used by other groups with experimental
deep HCA protocols.
Reliable and refined assessment and grading can
only be as good as the initial histologic preparations,
or at least this is a limiting factor. Benchmark studies
in the 1960s and 1970s established that perfusion fix-
ation followed by a period of in situ fixation before
any mechanical manipulation of brain and spinal
cord is markedly superior in terms of histologic
results to the immersion fixation technique used in
the present study.1 Removal and handling before fix-
ation, however gentle, produces artifacts, specifically
vacuolation and dark neurons (so-called “blue-neu-
ron” artifact). This happens even in neurosurgical
biopsy specimens. A postmortem interval before fix-
ation may also produce varying degrees of autolytic
change depending on the precise conditions of time
and temperature. In defense of immersion fixation, it
should be acknowledged that this is essentially the
method, whatever its limitations, routinely used in
human autopsies, but this only underscores the hand-
icap under which the clinical neuropathologist must
function. Also, some studies, although not the present
one, may combine histologic findings with tech-
niques that are incompatible with fixation, and work-
ing with “suboptimal” material is unavoidable.
Awareness of some of the histologic vagaries indi-
cates the pitfalls in constructing a histologic scoring
system. For one thing, a satisfactory system must not
mix effects that are probably artifact and genuine
hypoxic-ischemic injury. In the present study it is pos-
sible that grade 1 lesions represent artifactual change—
vacuolation and dark neurons that result from removal
and bisection of unfixed brain and subsequent immer-
sion fixation.
A grading scheme should probably consist of steps
that are reliably distinguishable and are accepted or
can be demonstrated to result from increasingly
severe degrees of the same underlying pathologic
process or insult. Presumably one does not arrive at
the more severe stages without passing through the
milder stages. A clue to the reliability of the grading
scheme may be that the milder grades are present at
the periphery of more severe lesions. It adds consid-
erable complexity to have an element in this
sequence that is an “independent” feature. Systems
like this are used, for example, in some brain tumor
grading schemes. In those cases, typically each fea-
ture is graded as present or absent and a “severity
score” is the sum of the features present. Scoring this
way raises its own questions: Are all features equally
significant?
For hypoxic-ischemic injury several groups have
adopted schemes that give progressively higher scores
to more severe lesions.2,3 The present authors’ system
varies somewhat from the usual practice. Their grades
are as follows: 1 = edema; 2 = hemorrhages, more
severe; and 3 = infarct, most severe. At the same time,
Table III, in which given areas have scores greater than
3, seems to imply treating these as “features” rather
than “grades.” Some of the underlying assumptions are
arguable or at least not clear.
Specifically, an unusual intermediate grade, “2 =
hemorrhages,” has been tucked in. Hemorrhages are
not typically a part of hypoxic-ischemic injury. They
may result from effects related to the bypass procedure,
altered coagulation status, and, of course, there can be
hemorrhage into infarcted tissue. However, this last
should be subsumed under the infarct in terms of grad-
ing. It is possible that they are an acute phenomenon,
but introducing a mix of acute (hours) and subacute
(days) changes complicates interpretation. That an
acute change should be present at 1 week is surprising. 
My suspicion is that the histologic material supports
only 2 grades, “no damage” and “definite hypoxic-
ischemic injury,” the authors’ grades 0 and 3, respec-
tively. Fortunately, it appears that restricting evaluation
to this more coarse level would not alter the authors’
conclusions. Within the sensitivity of the methods, no
significant neuroprotective effect of memantine was
discerned. Still, the authors previously found their eval-
uation sufficiently sensitive to recognize a positive neu-
roprotective effect of a different agent in a technically
similar study.4
It should  be recognized that there are difficulties
facing any investigator using neurohistologic assess-
ment in large animal models. Many parameters are
well studied in rodents and in paradigms where the
aim is to produce hypoxic-ischemic injury, but these
are not so well worked out in the intentionally milder
conditions used in experimental surgical models of
deep HCA or in dogs and piglets. Using numbers of
large animals to work out baseline patterns for vari-
ables that may affect damage, such as time after
injury and age of animals, is not practical.
Manipulations such as placement of indwelling
microperfusion catheters, as in the present study, or
thermal probes further perturb intracranial pressure,
cerebral blood flow, and the final histologic damage.
And the experimenter is trapped in the “Catch-22”
that damage that is survivable is only discernible by
means of standard techniques after several days and
will be relatively mild; damage sufficient to be read-
ily identified at short intervals (such as hemorrhages
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in this study or acute vacuolation described in other
studies5) is likely to preclude survival and is hardly a
realistic model with which to refine surgical proce-
dures. The best neurohistology achievable can be
some help with this.
Hart G. W. Lidov, MD, PhD
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